Transaction · 0001193125-26-418308

Berard Todd

Berard Todd, CMO, reported a transaction classified as return at BIOLIFE SOLUTIONS INC involving 194786.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DCMO
BLFSBIOLIFE SOLUTIONS INC
Filing timeOct 09
Trade dateOct 06, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableCalculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$38.61
Pre-filing
1mo ago1w ago +1.6%1d ago +0.0%
Returns since
7d30d90d180d1y

BLFS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
BLFS since 2026-10-09Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
return
Code D
Identifier
0001193125-26-418308
Common Stock
Transaction date
Oct 06, 2026
Filed Oct 09, 2026, 01:55 AM · 3d delay
Shares
194k sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
0 sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
-2score
Filing-only score

-2

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Marketing Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger S…

  2. F2

    The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the re…

  3. F3

    The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effect…

  4. F4

    Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

Original filing · 0001193125-26-418308
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

BLFS